A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Inclusion Criteria: * Adult subjects (18 years and older) with histologically or cytologically of advanced (metastatic or inoperable) advanced solid tumors. * Tumor (either an archival specimen or a fresh biopsy) shows NY-ESO-1 expression of 1+ by IHC (H-score). NY-ESO-1 expression must be confirmed by central validated assay. * Patients with NY-ESO-1 expressing solid tumors will be included. Patients must have received, been intolerant of, or been ineligible to receive at least 2 lines of the current standard of care therapy including but not limited to chemotherapy, immunotherapy and/or targeted therapy when appropriate (e.g. Atezolizumab is approved for use in patients with alveolar soft part sarcoma) according to their disease: * Inoperable or metastatic (advanced) ovarian, primary peritoneal or fallopian tube carcinoma: * Has received platinum containing chemotherapy and has platinum refractory or resistant disease that has progressed on second line therapy * If platinum sensitive disease, should have received ≥2 lines of chemotherapy. * May have received PARP inhibitors, bevacizumab or other targeted VEGF inhibitor therapy * Inoperable or metastatic (advanced) soft tissue sarcoma: * Subjects must have previously received either an anthracycline or ifosfamide containing regimen. * Gastrointestinal stromal tumors are eligible, but only must have previously received KIT-targeted therapy if a sensitizing mutation is present. * Angiosarcomas are eligible, but only must have…